Canon Virginia, Inc. (CVI) and Rebion announce production for Rebion’s blinq.® vision scanning technology, the first FDA cleared device designed to detect micro-strabismus and amblyopia (lazy eye) in children ages two through eight. With its portable design, blinq.® offers an easy and efficient method for pediatricians and front-line vision screening organizations to screen children, obtain immediate results, and support efforts to eradicate a condition that impacts three to five percent of the population.
In 2017, Rebion was awarded an MLSC grant through the MassRamp program. The program provided supplemental grant funding, on a competitive basis, to companies that have been awarded Small Business Innovation Research (SBIR) or Small Business Technology Transfer (STTR) Phase I grants or contracts from federal agencies. The goal of the program was to bridge the funding gaps associated with the long life sciences R&D cycle, and the high cost of translating research into commercially viable products. About $3,000,000 in grant funding was distributed through MassRamp to eight awardees.